Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
· 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
hla
hla-a2 positive cells present, refractory melanoma, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
#995651
Sacituzumab Govitecan Plus EV in Metastatic UC
#995652
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
#995654
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
#995650
Effects of Multimodal Exercises Integrated With Cognitive-behavioral Therapy in Subjects With Chronic Neck Pain
#995653
Record
· ID 848009
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.